NEXENTIS TECHNOLOGIES INC. Contingent Consideration Classified as Equity, Fair Value Disclosure
NEXENTIS TECHNOLOGIES INC. (NXTS) had Contingent Consideration Classified as Equity, Fair Value Disclosure of $385.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure · last filed 2026-08-13
- 2026-06-30: Contingent Consideration Classified as Equity, Fair Value Disclosure $385.00K.
- 2026-03-31: Contingent Consideration Classified as Equity, Fair Value Disclosure $929.00K.
- 2025-12-31: Contingent Consideration Classified as Equity, Fair Value Disclosure $2.14M.
| Period end | Contingent Consideration Classified as Equity, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $385.00K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $929.00K 10-Q · filed 2026-05-14 |
| 2025-12-31 | $2.14M 10-Q · filed 2026-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |